TrueBinding (former Immutics) Revenue and Competitors
Estimated Revenue & Valuation
- TrueBinding (former Immutics)'s estimated annual revenue is currently $12.9M per year.
- TrueBinding (former Immutics)'s estimated revenue per employee is $155,000
Employee Data
- TrueBinding (former Immutics) has 83 Employees.
- TrueBinding (former Immutics) grew their employee count by -32% last year.
TrueBinding (former Immutics)'s People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | SVP CMC | Reveal Email/Phone |
4 | Sr. Director Manufacturing, Site Head | Reveal Email/Phone |
5 | DIRECTOR VIVARIUM / IN VIVO | Reveal Email/Phone |
6 | Supply Chain Manager | Reveal Email/Phone |
7 | Facilities Manager | Reveal Email/Phone |
8 | BD manager | Reveal Email/Phone |
9 | Manufacturing Manager | Reveal Email/Phone |
10 | Senior Scientist, Mass Spectrometry | Reveal Email/Phone |
TrueBinding (former Immutics) Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is TrueBinding (former Immutics)?
Researching and developing first-in-class monoclonal antibody drugs to treat tumor, fibrotic diseases, metabolic diseases, autoimmune diseases and neurologic diseases.
keywords:N/AN/A
Total Funding
83
Number of Employees
$12.9M
Revenue (est)
-32%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $12M | 83 | 6% | N/A |
#2 | $35M | 86 | 48% | N/A |
#3 | $15M | 88 | 0% | N/A |
#4 | $12.5M | 89 | -29% | $126.5M |
#5 | $15M | 89 | -31% | N/A |